A5089375452- Renal cell carcinoma treatment
- Bladder and Urothelial Cancer Treatments
- Prostate Cancer Treatment and Research
- Cancer Genomics and Diagnostics
- Cancer Immunotherapy and Biomarkers
- Renal and related cancers
- Urinary and Genital Oncology Studies
- Microwave Engineering and Waveguides
- Cancer Diagnosis and Treatment
- Bone health and treatments
- Prostate Cancer Diagnosis and Treatment
- Multiple and Secondary Primary Cancers
- Testicular diseases and treatments
- Endoplasmic Reticulum Stress and Disease
- Cancer, Lipids, and Metabolism
- Pancreatic and Hepatic Oncology Research
- Urologic and reproductive health conditions
- Radiopharmaceutical Chemistry and Applications
- Economic and Financial Impacts of Cancer
- Ferroptosis and cancer prognosis
- Urological Disorders and Treatments
- Cancer, Hypoxia, and Metabolism
- Cardiac Structural Anomalies and Repair
- Electromagnetic Compatibility and Noise Suppression
- Pancreatic function and diabetes
Japanese Foundation For Cancer Research
2016-2025
Cancer Institute (WIA)
2023-2024
Cornell University
2023-2024
The Cancer Institute Hospital
2011-2023
Okazaki City Hospital
2005-2022
Tokyo Electron (Japan)
2021
Center for Cancer Research
2020
Shiga University
2020
Tokyo Ariake University of Medical and Health Sciences
2020
Aarhus University Hospital
2019
This study aimed to apply the International mRCC Database Consortium (IMDC) prognostic model in metastatic non-clear cell renal carcinoma (nccRCC). In addition, survival outcome of nccRCC patients was characterized.Data on 2215 (1963 with clear-cell RCC [ccRCC] and 252 nccRCC) treated first-line VEGF- mTOR-targeted therapies were collected from IMDC. Time treatment failure (TTF) overall (OS) compared groups favorable, intermediate, poor prognoses according IMDC criteriaThe median OS entire...
Purpose Obesity is an established risk factor for clear cell renal carcinoma (RCC); however, some reports suggest that RCC developing in obese patients may be more indolent. We investigated the clinical and biologic effect of body mass index (BMI) on treatment outcomes with metastatic RCC. Methods The impact BMI (high BMI: ≥ 25 kg/m 2 v low < ) overall survival (OS) outcome targeted therapy was 1,975 from International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) external...
There exists considerable biological and clinical variability between histologic variants of metastatic renal cell carcinoma (mRCC). Data reporting on patterns metastasis in mRCC are sparse.To characterize sites their association with survival across the 3 most common mRCC: clear (ccRCC), papillary (pRCC), chromophobe (chrRCC).In this multicenter, international cohort study, International Database Consortium (IMDC) database was used to identify consecutive patients starting systemic therapy...
The combination of immuno-oncology (IO) agents ipilimumab and nivolumab (IPI-NIVO) vascular endothelial growth factor targeted therapies (VEGF-TT) combined with IO (IO-VEGF) are current standard care first-line treatments for metastatic renal cell carcinoma (mRCC).
The condensin complex in frog extracts, containing two SMC (structural maintenance of chromosomes) and three non-SMC subunits, promotes mitotic chromosome condensation, its supercoiling activity increases during mitosis by Cdc2 phosphorylation. Here, we report that fission yeast has the same five-member complex, each which is essential for condensation. was purified subunits were identified microsequencing. Cnd1, Cnd2, Cnd3, showing a high degree sequence conservation to are viability, their...
The mainstay in the management of invasive bladder cancer continues to be radical cystectomy. With regard improvement quality life, however, therapies that preserve are desirable. We investigated use intravesical PLK-1 small interfering RNA (siRNA) against cancer. Patients with cancers expressing high levels have a poor prognosis compared patients low expression. Using siRNA/cationic liposomes, expression endogenous could suppressed cells time- and dose-dependent manner. As consequence,...
This study aims to assess the efficacy and safety of sunitinib in Japanese patients with metastatic renal cell carcinoma (RCC).Fifty-one prior nephrectomy, 25 treatment-naive (first-line group) 26 cytokine-refractory (pretreated were enrolled this phase II trial. Patients received 50 mg orally, once daily, repeated 6-week cycles (4 weeks on treatment, 2 off). The primary endpoint was RECIST-defined objective response rate (ORR) tumour assessments every 6 via computed tomography or magnetic...
Abstract BACKGROUND: Several promising molecular‐targeted drugs are used for advanced renal cancers. However, complete remission is rarely achieved, because none of the targets a key molecule that specific to cancer, or associated with “oncogene addiction” (dependence on one few oncogenes cell survival) cancer. Recently, an anaplastic lymphoma kinase (ALK) fusion, vinculin‐ALK, has been reported in pediatric carcinoma (RCC) cases who have history sickle trait. In this context, ALK inhibitor...
The optimal enzyme blend that maximizes human islet yield for transplantation remains to be determined. In this study, we evaluated eight different combinations (ECs) in an attempt improve yield. ECs consisted of purified, intact or truncated class 1 (C1) and 2 (C2) collagenases from Clostridium histolyticum (Ch), neutral protease (NP) Bacillus thermoproteolyticus rokko (thermolysin) Ch (ChNP).We report the results 249 isolations, including 99 deceased donors (research n=57, clinical n=42)...
Patients with brain metastases (BrM) from renal cell carcinoma and their outcomes are not well characterized owing to frequent exclusion of this population clinical trials. We analyzed data for patients or without BrM using the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC). A total 389/4799 (8.1%) had on initiation systemic therapy. First-line immuno-oncology (IO)-based combination therapy was associated longer median overall survival (OS; 32.7 mo, 95% confidence...
Abstract Nitrogen containing‐bisphosphonates (N‐BPs), widely used to treat bone diseases, have direct antitumor effects via the inactivation of Ras proteins. In addition activities, N‐BPs expand gdγδT cells, which exhibit major histocompatibility complex‐unrestricted lytic activity. BPs accumulate intermediate metabolites may be tumor antigens in target cells. The purpose our study was clarify cytotoxicity gdγδ T cells expanded ex vivo by most potent N‐BP, zoledronate (ZOL). Especially, we...
BackgroundIn a phase II, open-label, multicentre Japanese study, sunitinib demonstrated antitumour activity and acceptable tolerability in metastatic renal cell carcinoma patients. Final survival analyses updated results are reported.
Limited data exist on outcomes for metastatic renal cell carcinoma (mRCC) patients treated with multiple lines of therapy. Benchmarks survival are required patient counselling and clinical trial design. Outcomes mRCC from the International Database Consortium database 1, 2, or 3+ targeted therapy (TT) were compared by proportional hazards regression. Overall (OS) progression-free (PFS) calculated using different population inclusion criteria. In total, 2705 TT which 57% received only...
BACKGROUND To the authors' knowledge, outcomes and prognostic tools have yet to be clearly defined in patients with metastatic renal cell carcinoma (mRCC) who are treated immuno‐oncology (IO) checkpoint inhibitors (programmed death‐ligand 1 [PD‐L1] inhibitors). In current study, authors aimed establish IO efficacy benchmarks mRCC update patient each International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) class. METHODS A retrospective analysis was performed using IMDC...